Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam reports positive results from Phase II RSV study
The Gemini study was designed to evaluate the safety and anti-viral activity of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. The Gemini
The Gemini study was designed to evaluate the safety and anti-viral activity of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. The Gemini
The research showed that Sterilox Solution completely inactivated the H5N1 test strain and passed the US Environmental Protection Agency’s recommended hard-surface disinfection test, which requires two-minutes contact time.
The multiple dose study will be conducted in healthy, post-menopausal women. Subjects will receive four monthly subcutaneous doses of either ACE-011 or placebo. The primary objective of the
The notes are convertible into shares of the company’s common stock at an initial conversion rate of 38.6548 shares per $1,000 principal amount of the notes, subject to
Celgene Cellular Therapeutics (CCT) will perform testing of Homspera in order to evaluate the potential impact on cellular products in the company’s development pipeline. ImmuneRegen believes that Homspera
The primary focus will be a global, three-arm pivotal controlled trial that will evaluate two 24-week telaprevir-based regimens in approximately 1050 treatment-naive genotype 1 hepatitis C virus (HCV)
The primary objective of this Phase II study, which will be conducted at multiple sites in Canada, will be to determine the antitumor activity of MKC-1 administered orally
CH-1504, a non-metabolized antifolate, is said to be engineered to provide the same potent efficacy as methotrexate (MTX) but without the side effects caused by the metabolic breakdown
HspE7 is an investigational therapeutic vaccine targeting human papillomavirus (HPV)-related diseases. The trial is expected to dose up to five cohorts comprising twenty-four patients. The first cohort of
The decision was made in light of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with the liquid Leukine 500mcg